![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
STATEMENT OF NEED
There are an estimated 13,800 new cases of cervical cancer in the United States each year, and 4,290 people die of the disease (ACS, 2020). Deaths have declined during the past few decades due to screening and heightened awareness, yet this malignancy continues to be a global health concern and is considered an epidemic in parts of the world. A significant proportion of patients develop advanced disease, which is rarely curable with available therapies, and treatment is often limited to palliative care (NCCN, 2020). The 5-year overall survival rate is 56% for women with regional disease and 17% for those with distant disease; amongst black women, the prognosis is worse (Siegel et al, 2020).
TARGET AUDIENCE
Oncologists, gynecologists, physician assistants, nurse practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with cervical cancer.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Evaluate the utility of biomarker testing in the management of advanced cervical cancer
Assess recent clinical trial data on the use of novel immunotherapies in the treatment of recurrent and metastatic cervical cancer
Evaluate strategies to manage adverse events associated with novel immunotherapies for cervical cancer
FACULTY
Bradley J. Monk, MD, FACS, FACOG (Chairperson) Professor of Gynecologic Oncology University of Arizona College of Medicine
Jennifer Filipi, MSN, FNP-C Nurse Practitioner Massachusetts General Hospital
REGISTRATION
There is no fee to participate in or claim CME/NCPD credit for this activity.
Provided by i3 Health